research Tumor suppressor activity of ODC antizyme in MEK-driven skin tumorigenesis
Antizyme slows skin tumor growth by reducing cell growth in mice.
Search
for
Sort by
Research
510-540 / 1000+ results
research Expression of concern: potential risk for developing severe COVID-19 disease among anabolic steroid users
Anabolic steroid users may face higher risk of severe COVID-19.
research Dermo-Follicular Proliferation
Minoxidil and a solvent mixture can prevent hair loss caused by chemotherapy in mice.
research Repurposing With Purpose: Treatment of Bachmann–Bupp Syndrome With Eflornithine and Implications for Other Polyaminopathies
Eflornithine improved symptoms in Bachmann–Bupp Syndrome patients.
research Therapeutic Potential of Brassinosteroids in Biomedical and Clinical Research
Brassinosteroids may be useful in treating cancer, infections, and other diseases.
research SYSTEMATIC REVIEW OF ORAL JANUS KINASE INHIBITORS IN ALOPECIA AREATA: INSIGHTS FROM 2020 TO 2025 STUDIES
Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.
research 5α-Reductase inhibitors, antiviral and anti-tumor activities of some steroidal cyanopyridinone derivatives
Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.
research Distribution of SALT Scores with Ritlecitinib Treatment up to 24 months from the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.
research SARMS vs. anabolic steroids: comparative analysis of mechanisms, effects and health implications
research Non-hemorrhage-related adverse effects of rivaroxaban
Rivaroxaban can cause liver injury, allergic reactions, blood vessel inflammation, and hair loss, but these side effects are rare.
research 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.
research Optimization of minoxidil microemulsions using fractional factorial design approach
The study found a way to improve a skin-applied minoxidil formula using a specific design method.
research Pharmacological Profile of 9,11-Dehydrocortexolone 17α-Butyrate (CB-03-04), a New Androgen Antagonist with Antigonadotropic Activity
CB-03-04 shows promise as a treatment for prostate issues due to its strong anti-androgen effects.
research Nanocrystal Structure of Minoxidil: A Safe Stimulator for Hair Growth Factor for C57BL/6 Mice
Minoxidil nanocrystals improved hair growth in mice more effectively and safely than regular Minoxidil.
research Monilethrix with Acitretin
Acitretin improved monilethrix symptoms temporarily, but they returned after stopping treatment.
research 158 Novel effects of ivermectin in rosacea: reduction of erythema, flushing, skin texture, and invisible symptoms
Ivermectin 1% cream effectively reduces visible and invisible symptoms of rosacea.
research Novel Drugs Targeting Retinoic Acid Receptors
Newer retinoid drugs are effective for skin conditions but have significant side effects.
research Agaricus Subrufescens Ameliorates Ovarian Dysfunction and Regulates Altered Biochemical Parameters in Rats with Letrozole Induced Polycystic Ovarian Syndrome
Agaricus subrufescens extract improved ovarian function and normalized various health markers in rats with PCOS.
research Quintaquinone, a Merosesquiterpene from the Yellow Sponge Verongula cf. rigida Esper
A new compound from a sponge strongly inhibits an enzyme linked to male-pattern hair loss without being toxic at low levels.
research Evaluation of the protection of astaxanthin on human hair follicle palilla cells against the aging effects triggered by hydrogen peroxide
Astaxanthin may help protect hair cells from damage and prevent hair loss.
research Transferosomes versus transethosomes for the dermal delivery for minoxidil: Preparation and in vitro/ex vivo appraisal
Minoxidil, a hair loss treatment, works better and has fewer side effects when put into tiny particles called transethosomes, especially those containing oleic acid.
research 17-Oximino-5-androsten-3β-yl esters: synthesis, antiproliferative activity, acute toxicity, and effect on serum androgen level
Some synthesized compounds were more effective than Finasteride in reducing prostate cancer cell growth and androgen levels.
research Botryococcus terribilis Ethanol Extract Exerts Anti-inflammatory Effects on Murine RAW264 Cells
Botryococcus terribilis Ethanol Extract may reduce inflammation by changing gene expression in cells.
research Efficacy, safety and dose response of STS01, a topical controlled release nanoparticle formulation (dithranol/Prosilic), in adults with mild to moderate patchy alopecia areata: A randomised, double-blind, multicentre, phase 2 trial
STS01 1% effectively promotes hair regrowth with minimal side effects.
research Sulfation of minoxidil by human liver phenol sulfotransferase
Minoxidil activates hair growth by being sulfated by P-PST in the human liver.
research New approach to 3-oxo-4-aza-5α-androst-1-ene-17β-(--butylcarboxamide)
A new method was developed to make finasteride for treating hair loss.
research Natural Product-InspiredBis(trifluoromethyl) PhenylHydroxycinnamate Derivatives as Promising Nonsteroidal Inhibitorsof Human Steroid 5α-Reductase Type-1: Synthesis, InVitro, and In Silico Studies
Certain hydroxycinnamate derivatives may effectively inhibit enzymes linked to hair loss with low toxicity.
research Minoxidil opens mitochondrial KATP channels and confers cardioprotection
Minoxidil protects heart and improves recovery.
research NEW NON SYNTHETIC MOLECULES ARE ABLE TO INHIBIT APOPTOSIS IN DERMAL PAPILLAR CELLS OF HAIR BULB
New molecules can prevent cell death in hair follicles.
research Drug interactions between common dermatological medications and the oral anti-COVID-19 agents nirmatrelvir-ritonavir and molnupiravir
Some skin medications can have harmful interactions with the COVID-19 drug nirmatrelvir-ritonavir, but not with molnupiravir.